Everything below concerns LY3437943. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
=== Myocardium / cardiomyopathy === (I40) Acute myocarditis (I41) Myocarditis in diseases classified elsewhere (I42) Cardiomyopathy (I42.0) Dilated cardiomyopathy (I42.1) Obstructive hypertrophy cardiomyopathy (I42.2) Other hypertrophic cardiomyopathy (I42.3) Endomyocardial (eosinophilic) disease Eosinophilic myocarditis Endomyocardial (tropical) fibrosis Löffler's endocarditis (I42.4) Endocardial fibroelastosis (I42.5) Other restrictive cardiomyopathy (I42.6) Alcoholic cardiomyopathy (I42.8) Other cardiomyopathies Arrhythmogenic right ventricular dysplasia (I43) Cardiomyopathy in diseases classified elsewhere
==== Hypothermia ==== On 16 January 2024, doctors reported children weakened by starvation were dying from hypothermia. An ActionAid coordinator stated on 27 January 2024 that children without winter coats were suffering from the cold and rainfall of the winter months, with new commercial products prevented from being brought in. An Al Jazeera correspondent reported he had witnessed children sleeping in cold, mud-filled tents. One father stated in an interview on 2 February 2024, " It’s so freezing. Even my children can’t. One to two blankets aren’t enough at all. I have a newborn baby. I fear he will be ill every other day." Children in Rafah were dressed in remaining PPE equipment from the COVID-19 pandemic in order to keep warm. In Deir al-Balah, children burned books to keep warm.
The pericardium (pl. pericardia), also called pericardial sac, is a fluid filled sac containing the heart and the roots of the great vessels. It has three layers, an outer layer made of strong inelastic connective tissue (fibrous pericardium), and a double-layered inner membrane serous membrane (serous pericardium), between which the pericardial fluid is contained. It encloses the pericardial cavity, which contains pericardial fluid, and defines the middle mediastinum. It separates the heart from interference of other structures, protects it against infection and blunt trauma, and lubricates the heart's movements.
Sources: en.wikipedia.org
Tyrosine is the non-essential amino acid precursor of melanin. Tyrosine is converted to dihydroxyphenylalanine (DOPA) via the enzyme tyrosinase. Then DOPA is polymerized into melanin. The copper-ion based enzyme-catalyzed oxidative transformation of catechol derivative dopa to light absorbing dopaquinone to indole-5,6-quinone is clearly seen following the polymerization to melanin, the color of the pigment ranges from red to dark brown.
The Rhodesian army continued its "mobile counter-offensive" strategy of holding key positions ("vital asset ground") while carrying out raids into the no-go areas and into neighbouring countries. While often extraordinarily successful in inflicting heavy guerrilla casualties, such raids also on occasion failed to achieve their objectives. In April 1979 special forces carried out a raid on Joshua Nkomo's residence in Lusaka, Zambia, with the stated intention of assassinating him. Nkomo and his family left hastily a few hours before the raid – having clearly been warned that the raid was coming. In 1979, some special forces units were accused of using counterinsurgent operations as cover for ivory poaching and smuggling. Colonel Reid-Daly (commander of the Selous Scouts) discovered that his phone was bugged and after challenging a superior officer on this issue was court martialled for insubordination. He received the lightest sentence possible, a caution, but he continued to fight his conviction and eventually resigned his commission and left the Army. By 1978–1979, up to 70% of the regular army was composed of black soldiers (though both the army and police reserves remained overwhelmingly white). By 1979 there were also 30 black commissioned officers in the regular army. While there was never any suggestion of disloyalty among the soldiers from predominantly black units (in particular within the Selous Scouts or the Rhodesian African Rifles – RAR), some argue that, by the time of the 1980 election, many of the RAR soldiers voted for Robert Mugabe.
=== Mantle minerals === Ferropericlase (Mg,Fe)O, a solid solution of periclase (MgO) and wüstite (FeO), makes up about 20% of the volume of the lower mantle of the Earth, which makes it the second most abundant mineral phase in that region after silicate perovskite (Mg,Fe)SiO3; it also is the major host for iron in the lower mantle. At the bottom of the transition zone of the mantle, the reaction γ-(Mg,Fe)2SiO4 ⇌ (Mg,Fe)SiO3 + (Mg,Fe)O transforms γ-olivine into a mixture of silicate perovskite and ferropericlase and vice versa. In the literature, this mineral phase of the lower mantle is also often called magnesiowüstite. Silicate perovskite may form up to 93% of the lower mantle, and the magnesium iron form, (Mg,Fe)SiO3, is considered to be the most abundant mineral in the Earth, making up 38% of its volume.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.